Home > Boards > US Listed > Biotechs >

Sonnet BioTherapeutics Inc (SONN)

Add SONN Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 12/2/2020 9:12:22 AM - Followers: 58 - Board type: Free - Posts Today: 1

UPDATED; Mon, November 30, 2020, 6:30 AM MST
#2 $SONN This study is an important milestone for SON-1010, and we believe further validates the fundamental strengths of our drug development platform."

Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010
Mon, November 30, 2020, 6:30 AM MST
Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies

SON-1010 continues to be well tolerated at doses far exceeding levels expected in potential future clinical trials, without producing detectable cytokine imbalances

Analysis of Interferon-γ levels, a key biomarker of antitumor activity, suggest potent on-target pharmacodynamic (PD) effects

PRINCETON, NJ / ACCESSWIRE / November 30, 2020 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs,
announced today that it has successfully completed a non-human primate (NHP) study of SON-1010, a proprietary fully human Interleukin 12 (IL-12) therapeutic candidate configured using
Sonnet's Fully Human Albumin Binding (FHAB) platform.
Sonnet's FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose-sparing and an opportunity to improve the safety and efficacy profile of IL-12, as well as other immunomodulators.
The objectives of this dose range-finding study were twofold: to confirm the enhanced PK profile of SON-1010 in comparison to recombinant human IL-12 (demonstrated previously in a humanized mouse model),
and to perform a dose escalation to inform and de-risk the design of follow-on NHP studies needed for the SON-1010 IND filing with the FDA.

Pankaj Mohan, Ph.D., Founder and CEO, commented, "We are excited by these data that indicate a potentially broad therapeutic window for SON-1010,
our proprietary FHAB-Interleukin 12 drug candidate. IL-12 is widely viewed as holding promise as a therapeutic in the oncology setting,
however, this application has been limited by its toxicity and pharmacokinetic profile.
We believe today's announcement represents another important step forward towards unlocking the therapeutic potential of IL-12, as well as other compounds in our pipeline."

Dr. Hossein Borghaei, D.O., M.S., a member of Sonnet's Scientific Advisory Board and Chief of Thoracic Medical Oncology at Fox Chase Cancer Center, commented,
"The encouraging results from this non-human primate study suggest that the IL12-FHAB may be well tolerated in humans. Along with further toxicology studies,
we believe this work sets the table for future potential clinical trials in lung cancer and head and neck cancers."

The data from this study indicate that in healthy cynomolgus macaques of both sexes,
a single dose of SON-1010 is well tolerated at dosage levels greater than 50 times the anticipated exposure in human clinical trials.
Additionally, SON-1010 elicited a prolonged and potent on-target PD effect as measured by, Interferon-γ (IFN-γ), a key biomarker of antitumor activity.
On-target and transient changes in clinical chemistry and pathology parameters were observed, but resolved completely within 14 to 21 days post-dosing.
Signs of cytokine imbalance, or uncontrolled increase of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6 were notably absent from all dose levels tested in the study.
Pharmacokinetic analysis of serum samples from the study animals indicated a mean half-life of 40.0 (±6.9) hours for subcutaneous dose routes and 27.45 (±2.8) hours for intravenous dose routes.
These results build on those from a prior study using the B16F10 mouse model of melanoma,
where the mouse version of SON-1010 showed a 20-fold reduction in the dosage required to achieve a similar therapeutic effect compared to mouse IL-12.
Taken together, the observed extended half-life, improved therapeutic window and reduced dosing requirement, made possible by Sonnet's FHAB technology,
represent key advantages of SON-1010 as a potential immune oncology therapeutic.

John Cini, Ph.D., Co-founder and Chief Scientific Officer, added, "We designed our FHAB technology to leverage the therapeutic properties of otherwise toxic immune modulating compounds,
by optimizing their tolerability and adding a targeted delivery mechanism.
This study is an important milestone for SON-1010, and we believe further validates the fundamental strengths of our drug development platform."

Results from the second phase of this NHP study, which includes a repeat dose regimen in healthy cynomolgus macaques, are expected in the coming weeks.
Collectively, these data will be applied to advance SON-1010 to potential first-in-human Phase I clinical testing in patients with solid tumors,
specifically lung cancer and head and neck cancers, with an IND submission anticipated during the second half of 2021.

About Sonnet BioTherapeutics Holdings, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action.
Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv)
that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues.
Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs.
FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the timing of an IND submission, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Alan Lada
Solebury Trout

SOURCE: Sonnet BioTherapeutics, Inc.

View source version on accesswire.com:

UPDATE 08-24-2020

JUST IN: $SONN 3 Penny Stocks To Watch After Trump's Emergency Plasma Authorization

Convalescent Plasma Stocks To Watch Penny stocks shift in an instant and that could be the case for a few companies this week. 

Over the weekend, U.S. President Donald Trump announced the emergency authorization of convalescent plasma for COVID-19. 

At a press briefing that began at 5:30 PM ES...

Read the whole news SONN - 3 Penny Stocks To Watch After Trump's Emergency Plasma Authorization

Sonnet BioTherapeutics Holdings Inc. (SONN)

UPDATE; 08-05-2020


Powering a New Wave of Immune Therapeutics

At Sonnet BioTherapeutics, we are taking the fight directly to cancer. Our proprietary FHAB™ (Fully Human Albumin Binding) technology empowers
the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

About Sonnet BioTherapeutics


$SONN COULD IT BE DIS ????? +30% Sonnet BioTherapeutics Signs Letter Of Intent For Potential Licensing Of Neuropathies Asset To New Life Therapeutics;
Co. To Receive $500K Payment At Signing And Up To $40M 
In Milestones And 30% Royalty On Commercial Sales
7:36 am ET August 4, 2020 (Benzinga) Print
Potential Collaboration in Diabetic Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy for ASEAN Region

500,000 Non-Refundable Payment to Sonnet on Signing of Letter of Intent
Potential for up to $40 Million in Milestone Payments and 30% Royalty on Commercial Sales

PRINCETON, NJ / ACCESSWIRE / August 4, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), 

a biopharmaceutical company developing innovative targeted biologic drugs,
announced today that it has executed a letter of intent to negotiate an agreement to license its SON-081 and SON-080 assets, 

both low-dose formulations of Interleukin 6 (IL-6), for diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral 

neuropathy (CIPN) to New Life Therapeutics Pte. Ltd. ("New Life") of Singapore. 

The licensed territory would include the ASEAN countries of Singapore, Malaysia, Indonesia, Thailand, The Philippines, Cambodia, Brunei, Vietnam, Myanmar and Lao PDR.

The transaction is subject to execution of a definitive agreement to be negotiated between Sonnet and New Life. 

Sonnet received a $500,000 non-refundable payment upon execution of the letter of intent from New Life. 

The letter of intent outlines an agreement that could total to Sonnet up to $40 million in milestone payments and a royalty of 30% on commercial sales.

Pankaj Mohan, Ph.D., Founder and CEO of Sonnet commented, 
"We are excited about the opportunity to partner with New Life to advance our neuropathy assets, especially in diabetic neuropathy. 

The potential agreement would not only afford Sonnet development reach into territories with compelling commercial market dynamics, 

but will also provide access to the future clinical data for enhancing additional potential partnering in other regions. 

Most importantly, I am hopeful that this asset could benefit patients suffering from debilitating neuropathy conditions."

"New Life was created to address critical unmet medical needs in the ASEAN Region in neuropathies, 
said Rakesh Aggarwal, CEO of New Life Therapeutics. 

"With the explosion of diabetes in this part of the world, 
we are excited for the potential to advance SON-081 which could help diabetic patients recover from the debilitating effects of peripheral diabetic neuropathies, 

subject to successful clinical trials and regulatory approval in the Territory. 

This is an important first step as we join forces with Singapore and other ASEAN countries to fight the war on diabetes." 

Aggarwal added, "We also look forward to the SON-080 opportunity in CIPN, an equally debilitating disease for cancer patients, 
representing another unmet medical need. 

This asset could potentially provide relief to patients battling chronic pain, loss of sensation and various motor neuron conditions."

Data from various animal models of neuropathy have demonstrated 
the potential of low dose IL-6 as a disease modifier. 

Low dose IL-6 treatment demonstrated neurorestorative properties that allowed nerve regrowth, reinstatement of physiological nerve conductance and restoration of nerve fiber density, 

which consequentially reduced pain and aberrant sensations in animals suffering from neuropathy. 

In addition, safety monitoring of previous clinical trials in thrombocytopenia that had enrolled more than 200 cancer patients undergoing chemotherapy
concluded that low-dose IL-6 was generally safe and well tolerated. 

SON-081 is an identical formulation of the same low-dose IL-6, SON-080, 

in development for chemotherapy-induced peripheral neuropathy, 

where low dose IL-6 is believed to work through a similar mechanism 
of action for neuroprotection, nerve growth and pain reduction. 

Upon execution of a definitive agreement, 
New Life Therapeutics will be responsible for conducting a Phase Ib/IIa pilot scale efficacy study with SON-081 in DPN, 

expected to initiate during the first half of 2021. A pilot scale efficacy study with SON-080 in CIPN will be conducted by Sonnet 
and is also expected to be initiated during the first half of 2021.

Gael Hedou, Ph.D., COO of Sonnet BioTherapeutics C.H. S.A. and 
one of the early developers of SON-081 stated: 

"I have worked on the IL-6 program for the treatment of neuropathies 
for several years, 
and this potential partnership with New Life is an exciting step 
forward toward bringing this critically needed treatment to 
patients and to demonstrate the therapeutic potential of low dose IL-6." 

Dr. Hedou further commented, 
"the low levels of IL-6 that are naturally released by the muscles 
upon exercise is a key mediator of the beneficial effects of sport, including nerve health. 

This ability to release IL-6 is often hindered in diabetic patients and, furthermore, 
the intensity of exercise needed to release therapeutic levels of 
IL-6 is not generally possible in the daily routine of these patients. 

Low dose IL-6 intermittently administered to DPN patients reaching physiologically active levels, 
has the potential to alleviate patient's condition by regrowing 
nerves and ultimately by normalizing sensations that are affected by neuropathic disease."

About Sonnet BioTherapeutics Holdings, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. 

Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes 
a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. 

FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes,
including cytokines, peptides, antibodies and vaccines.

© 2020 http://www.Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Sonnet Pipeline

Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates, with a lead compound, SON-080, ready to enter Phase 2 development.

Program Indications Discovery Preclinical Phase 1 Phase 2
SON-080 (low-dose IL-6) Chemotherapy Induced Peripheral Neuropathy
Discovery Phase complete
Pre-clinical Phase complete
Phase I Phase in progress
Phase II Phase not started
SON-081 (low dose IL-6) Diabetic Peripheral Neuropathy
Discovery Phase complete
Pre-clinical Phase complete
Phase I Phase in progress
Phase II Phase not started
SON-1010 (IL12-FHAB) Undisclosed Solid Tumor
Discovery Phase complete
Pre-clinical Phase in progress
Phase I Phase not started
Phase II Phase not started
SON-1210 (IL15-FHAB-IL12) Undisclosed Solid Tumor
Discovery Phase complete
Pre-clinical Phase in progress
Phase I Phase not started
Phase II Phase not started
SON-2014 (GMcSF-FHAB-IL18) Early Stage Cancer
Discovery Phase in progress
Pre-clinical Phase not started
Phase I Phase not started
Phase II Phase not started
SON-3015 (Anti-IL6-FHAB-Anti-TGFβ) Tumor and Bone Metastases

A Modular Drug Development Platform

Our Fully Human Albumin Binding (FHAB) technology is the foundation of a modular, plug-and-play drug development platform with several distinct advantages:

  • Compatibility with many biologic drug classes, including interleukins, growth factors, peptides and vaccines
    Enhanced pharmacokinetics
    Targeted, directed activity for tumor selectivity
    Increased in vivo efficacy
    Single- or bi-specific mechanisms of action


Chanticleer Holdings Announces 1-for-26 Reverse Stock Split
Date : 03/31/2020 @ 4:07PM
Source : GlobeNewswire Inc.
Stock : Sonnet BioTherapeutics Inc (SONN)
Quote : 5.5727 0.4027 (7.79%) @ 10:17AM
Chanticleer Holdings Announces 1-for-26 Reverse Stock Split



Chanticleer Holdings, Inc. (Nasdaq: BURG)
(the “Company” or “Chanticleer”),
owner, operator and franchisor of multiple nationally-recognized restaurant brands,
today announced that it will effect a 1-for-26 reverse stock split of its outstanding common stock.

The reverse stock split will be effective for trading purposes as
of the commencement of trading on Thursday, April 2, 2020.

Chanticleer also announced today that the Nasdaq Stock Market has approved the continued listing of Sonnet BioTherapeutics Holdings, Inc.

on the Nasdaq Capital Market following its merger with Chanticleer, which is expected to close tomorrow,
April 1, 2020. As previously disclosed, in connection with the merger,

Chanticleer will spin off its restaurant operations.

Upon the closing of the merger,
Chanticleer will change its name to Sonnet BioTherapeutics Holdings, Inc.
and its common stock is expected to begin trading on the
Nasdaq Capital Market on Thursday, April 2, 2020 on a post
reverse stock split basis under the symbol “SONN”.

The reverse stock split is intended to increase the per share
trading price of Chanticleer common stock to satisfy the minimum
bid price requirement for continued listing on
The Nasdaq Capital Market after the completion of the merger.

Chanticleer’s common stock will continue to trade on
The Nasdaq Capital Market under the symbol “SONN” and under a
new CUSIP number 83548R105. As a result of the reverse stock split,

every 26 pre-split shares of common stock outstanding will become one share of common stock.

The par value of the common stock will remain unchanged at $0.0001 per share after the reverse stock split.

The reverse stock split will not change the authorized number of shares of the Company’s common stock.

The reverse stock split will affect all stockholders uniformly and
will not alter any stockholder’s percentage interest in the Company’s equity,
except to the extent that the reverse stock split results in some stockholders owning a fractional share.

No fractional shares will be issued in connection with the reverse split.

Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on today’s
closing price of the Company’s common stock as reported on Nasdaq.

The reverse split will also apply to common stock issuable upon the exercise of Chanticleer’s outstanding warrants and stock options,
with a proportionate adjustment to the exercise prices thereof,
and under the Company’s equity incentive plans.

The reverse stock split will reduce the number of shares of common
stock issued and outstanding from approximately 14.2 million to approximately 0.55 million (prior to the merger).

On March 18, 2020, the holders of a majority of the Company’s outstanding shares of common stock approved the reverse stock split
and gave the Company’s board of directors discretionary authority
to select a ratio for the split ranging from 1-for-2 to 1-for-40.

The board of directors approved the reverse stock split at a ratio of 1-for-26 on March 26, 2020.

As previously disclosed, the Company’s existing restaurant business, including its assets and liabilities, will be spun-off immediately
prior to the close of the merger into a newly created corporate entity.

This new entity will be named Amergent Hospitality Group
(“Amergent”) and will be wholly owned by Chanticleer’s shareholders owning common stock of record as of the close of business on Thursday,
March 26, 2020, the record date for the spin-off.

Securities Transfer Corporation is acting as the exchange agent
and transfer agent for the reverse stock split.

Stockholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse
stock split.
Beneficial holders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Chanticleer Holdings, Inc.

Headquartered in Charlotte, NC, Chanticleer Holdings owns, operates,
and franchises fast, casual,
and full-service restaurant brands, including American Burger Company,

BGR – Burgers Grilled Right, Little Big Burger, Just Fresh, and Hooters. For more information, please visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the closing of the merger.

All statements pertaining to Chanticleer Holdings, Inc.’s expectations regarding future financial and/or operating results,
potential for our tests and services and future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements.

Forward-looking statements involve risks and uncertainties discussed
in the Chanticleer Holdings, Inc.
Form 10-K for the year ended December 31, 2019, along with other
filings with the Securities and Exchange Commission.

These forward-looking statements speak only as of the date hereof.

Chanticleer Holdings, Inc. disclaims any obligation to update these forward-looking statements.

Chanticleer Holdings Investor Contact:

Jason Assad

Sonnet BioTherapeutics

Alan Lada

 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#1464  Sticky Note $SONN COULD IT BE DIS, up to $40mil.+30% mick 11/24/20 07:52:12 PM
#1469   The FDA has reissued the August 23, 2020 Kaad_g 12/02/20 09:12:22 AM
#1468   More news in the coming weeks. "Results from the Kaad_g 12/01/20 09:50:07 AM
#1467   thank you, a.h. upticking mick 11/30/20 04:08:31 PM
#1466   This is great news and an important milestone. Kaad_g 11/30/20 02:59:37 PM
#1465   #2 $SONN This study is an important milestone mick 11/30/20 09:33:58 AM
#1464   $SONN COULD IT BE DIS, up to $40mil.+30% mick 11/24/20 07:52:12 PM
#1463   Sonnet BioTherapeuti (SONN) mick 11/24/20 07:50:14 PM
#1462   There was a bid at $2.5 for over Kaad_g 11/07/20 09:05:14 AM
#1461   Liking how this trades in a weak market. naturalborninvestor 10/31/20 11:39:30 AM
#1460   shares are very thin. $SONN mick 10/25/20 08:23:53 PM
#1459   That's even better! elcheepo 10/25/20 05:12:14 PM
#1458   Sonnet BioTherapeuti (SONN) mick 10/25/20 05:08:25 PM
#1457   $SONN $7 mick 10/25/20 05:08:17 PM
#1456   Who set the target? elcheepo 10/15/20 08:26:57 PM
#1455   Soon, you will get $6+ Shane Chowdhury 10/15/20 08:25:55 PM
#1454   SONN $6 TARGET PRICE TODAY WOOHOOOOOOOOOO weedtrader420 10/12/20 04:58:17 AM
#1453   Sonnet could become a billion dollar company overnight, Kaad_g 10/10/20 10:47:28 AM
#1452   This analyst set a target of $8 Kaad_g 09/24/20 09:06:14 AM
#1451   awfully cheap, SONN 2.4900 -0.0300 -1.1905% USD 12:00PM EDT 259.398k mick 09/09/20 02:04:26 PM
#1450   $SONN spike areas,timing [3 MORE DAYS FER SPIKE mick 09/06/20 01:39:35 PM
#1449   Good luck here. I’m going to avoid it. RockstarStocks 09/05/20 03:28:52 PM
#1447   SONN i have been expecting dis but naked mick 09/05/20 03:27:50 PM
#1446   Agreed but unless it gaps up it’s going lower. RockstarStocks 09/05/20 03:25:22 PM
#1445   Sonnet BioTherapeuti (SONN) mick 09/05/20 03:23:43 PM
#1444   $SONN is way oversold imho mick 09/05/20 03:23:35 PM
#1443   $SONN Sep 01, 2020 8:30am EDT mick 09/01/20 09:19:45 AM
#1442   $SONN A Versatile Discovery Platform mick 09/01/20 09:18:17 AM
#1441   $SONN Sonnet Announces New Preclinical Data for SON-1010 mick 09/01/20 09:10:23 AM
#1440   $SONN reads outstanding imo. mick 09/01/20 09:03:11 AM
#1439   https://www.sonnetbio.com/news-media/press-releases/detail/20/sonnet-announces-n RockstarStocks 09/01/20 08:47:55 AM
#1438   $SONN chart read bearish but i read convergence mick 08/31/20 07:17:10 PM
#1437   $SONN WASHINGTON (AP) — President Donald Trump on mick 08/31/20 07:10:37 PM
#1436   AD MA mick 08/31/20 07:09:25 PM
#1435   i agree mick 08/31/20 07:06:35 PM
#1434   just noticed $SONN thanx for being mod wit mick 08/31/20 07:05:43 PM
#1433   Plasma is not where it’s at 30% success Biggin 1 08/29/20 04:26:50 PM
#1432   Insane what’s happened to $SONN. Should be soaring IMO. RockstarStocks 08/28/20 01:28:19 PM
#1431   Gap is closed, if it even matters here. acing58108 08/28/20 10:46:28 AM
#1430   Good spot to load iyo? JMMatthews 08/28/20 10:03:52 AM
#1429   $SONN WASHINGTON (AP) — President Donald Trump on mick 08/26/20 06:41:28 AM
#1428   I didn’t realized the warrants were priced around Jack8973902 08/26/20 01:14:22 AM
#1427   Grab some $AMNA while you’re at. Another plasma play. RockstarStocks 08/25/20 02:43:41 PM
#1426   I like bargains, and I'll even throw in Mr Krabs 08/25/20 02:40:38 PM
#1425   Hello Mr Krabs! Bargain prices right here. $SONN RockstarStocks 08/25/20 02:37:28 PM
#1424   Mr Krabs loves free money, I'll buy all Mr Krabs 08/25/20 02:34:01 PM
#1423   It wants to break out here! $SONN RockstarStocks 08/25/20 01:43:22 PM
#1422   Alright time to dig out if this hole RockstarStocks 08/25/20 01:26:40 PM
#1421   Here we go RockstarStocks 08/25/20 10:36:48 AM
#1420   Alright let’s move back up now RockstarStocks 08/25/20 10:25:19 AM
#1419   Added some 3.02 RockstarStocks 08/25/20 10:22:45 AM
Consent Preferences